12-9612: Anti-p40(IL-12/IL-23) monoclonal Antibody (Wezlana Biosimilar)

Application : FACS

Reactivity : Human

Alternative Name : Wezlana, west, Ustekinumab-auub

Isotype : IgG1,k

Description

Wezlana (Ustekinumab-auub) is a biosimilar to Stelera. The U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases. Ustekinumab is a fully human IgG1 monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin IL-12 and IL-23, which are involved in immune and inflammatory responses. IL-12 and IL-23 are produced by activated antigen-presenting cells as secreted heterodimeric cytokines that bind to receptor complexes in natural killer cells and T cells. Ustekinumab can effectively neutralizing both human IL-12 (Th1)-mediated and IL-23 (Th17)-mediated cellular responses.

Product Info

|	
Amount :	100 µg
Content :	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Reconstitute in sterile water.
Storage condition :	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature.

Application Note

FACS 1:100

Figure 1: Coomassie staining of SDS-PAGE gel loaded with Wezlana biosimilar mAb (Abeomics Cat# 12-9612) at 2 µg, 5 µg, 10 µg at reducing condition and 5 µg under non-reducing conditions.

Figure 2: ELISA plate pre-coated 1 μg/mL (50 μL/well) of human IL-23 protein can bind anti-IL-23 p40 neutralizing antibody.